Literature DB >> 18923372

Thyroid cancer in infants and adolescents after Chernobyl.

C Reiners1, Y E Demidchik, V M Drozd, J Biko.   

Abstract

Studies in children medically exposed to external irradiation more than 50 years ago revealed a considerably increased risk for thyroid cancer. Similarly, a strongly age-dependent risk for thyroid cancer was observed in the Japanese population after the atomic bomb explosions with the highest risk in the group of children below age of 10. After the Chernobyl accident, children from Belarus living in highly exposed regions received mean thyroid doses by radioactive fallout higher by a factor of approximately 2 as compared to the survivors of the atomic bomb explosions. This lead to a radiation related increase of thyroid cancer incidence in children and adolescents with the highest incidence in age group 0-4 years up to now totally amounting to approximately 5 000 cases. For screening of thyroid cancer in children, high resolution ultrasound is the method of choice which has to be complemented by fine-needle aspiration biopsy in suspicious cases. Diagnostic criteria for malignancy in childhood thyroid cancer by ultrasound are hypoechogenicity and irregularity of the outline, subcapsular location of lesions and increased peri-intranodular vascularisation. The treatment strategy for thyroid cancer in children does not differ substantially from the approach used in adults. Primary treatment consists of thyroidectomy and lymph node dissection. Careful and complete removal of the lymph nodes is of great clinical relevance in children because of very frequent node involvement (between 40% and 90%). Because of the high prevalence of lymph node metastases, ablation of thyroid remnants is mostly indicated in children with thyroid cancer. Distant metastases which need higher activities of radioiodine are less frequent with 10-20%. Even in advanced cases of childhood thyroid cancer, long-lasting remissions can be achieved. A specific finding in children is disseminated, milliary lung metastases with intense radioiodine uptake. In this situation, pulmonary fibrosis may be a severe side-effect so that the indication for repeated courses of radioiodine therapy has to be decided thoroughly. With respect to side-effects of radioiodine therapy, the risk of developing breast cancer has to be taken into account seriously since especially the female breast is exposed to a relatively high radiation dose. Generally, young patients treated with high activities of radioiodine should be carefully followed up during their whole lifespan.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18923372

Source DB:  PubMed          Journal:  Minerva Endocrinol        ISSN: 0391-1977            Impact factor:   2.184


  12 in total

1.  Pediatric thyroid cancers: an Indian perspective.

Authors:  Devendra A Chaukar; Abhishek D Vaidya
Journal:  Indian J Surg Oncol       Date:  2012-02-16

Review 2.  The treatment of differentiated thyroid cancer in children: emphasis on surgical approach and radioactive iodine therapy.

Authors:  Scott A Rivkees; Ernest L Mazzaferri; Frederik A Verburg; Christoph Reiners; Markus Luster; Christopher K Breuer; Catherine A Dinauer; Robert Udelsman
Journal:  Endocr Rev       Date:  2011-08-31       Impact factor: 19.871

Review 3.  Radioiodine for remnant ablation and therapy of metastatic disease.

Authors:  Christoph Reiners; Heribert Hänscheid; Markus Luster; Michael Lassmann; Frederik A Verburg
Journal:  Nat Rev Endocrinol       Date:  2011-08-09       Impact factor: 43.330

4.  Pulmonary fibrosis in youth treated with radioiodine for juvenile thyroid cancer and lung metastases after Chernobyl.

Authors:  Helge Hebestreit; Johannes Biko; Valentina Drozd; Yuri Demidchik; Antje Burkhardt; Andreas Trusen; Meinrad Beer; Christoph Reiners
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-05-28       Impact factor: 9.236

5.  Determinants of successful ablation and complete remission after total thyroidectomy and ¹³¹I therapy of paediatric differentiated thyroid cancer.

Authors:  Frederik A Verburg; Uwe Mäder; Markus Luster; Heribert Hänscheid; Christoph Reiners
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-06-13       Impact factor: 9.236

6.  Favourable course of disease after incomplete remission on (131)I therapy in children with pulmonary metastases of papillary thyroid carcinoma: 10 years follow-up.

Authors:  Johannes Biko; Christoph Reiners; Michael C Kreissl; Frederik A Verburg; Yuri Demidchik; Valentina Drozd
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-11-27       Impact factor: 9.236

7.  Success of the postoperative 131I therapy in young Belarusian patients with differentiated thyroid cancer after Chernobyl depends on the radiation absorbed dose to the blood and the thyroglobulin level.

Authors:  Heribert Hänscheid; Frederik Anton Verburg; Johannes Biko; Stefanie Diessl; Yuri E Demidchik; Valentina Drozd; Christoph Reiners
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-04-02       Impact factor: 9.236

8.  Differentiated thyroid carcinoma: comparison of histopathologic characteristics, clinical course, and outcome between young children and adolescents.

Authors:  M Motazedian; B Shafiei; P Vatankhah; S Hoseinzadeh; M Mirzababaee; L Fathollahi; M Ansari; N Baharfar; F Tabeie; I Neshandar Asli
Journal:  Med Oncol       Date:  2013-02-20       Impact factor: 3.064

9.  Clinical experiences with radiation induced thyroid cancer after chernobyl.

Authors:  Christoph Reiners
Journal:  Genes (Basel)       Date:  2011-05-31       Impact factor: 4.096

10.  Feasibility Study Shows Multicenter, Observational Case-Control Study Is Practicable to Determine Risk of Secondary Breast Cancer in Females With Differentiated Thyroid Carcinoma Given Radioiodine Therapy in Their Childhood or Adolescence; Findings Also Suggest Possible Fertility Impairment in Such Patients.

Authors:  Valentina Drozd; Rita Schneider; Tamara Platonova; Galina Panasiuk; Tatjana Leonova; Nataliya Oculevich; Irina Shimanskaja; Irina Vershenya; Tatjana Dedovich; Tatjana Mitjukova; Inge Grelle; Johannes Biko; Christoph Reiners
Journal:  Front Endocrinol (Lausanne)       Date:  2020-10-28       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.